1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
THR B 27 - PRO B 28 MODEL 2 OMEGA =213.93 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
THR B 27 - PRO B 28 MODEL 9 OMEGA =213.50 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION
Hua, Q.X.
Shoelson, S.E.
Inouye, K.
Weiss, M.A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
90
582
586
10.1073/pnas.90.2.582
8421693
Paradoxical structure and function in a mutant human insulin associated with diabetes mellitus.
1993
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
89
2379
Structure and Dynamics of Des-Pentapeptide-Insulin in Solution: The Molten-Globule Hypothesis
1992
UK
Nature
NATUAS
0006
0028-0836
354
238
Receptor Binding Redefined by a Structural Switch in a Mutant Human Insulin
1991
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2383.698
INSULIN
1
man
polymer
3373.857
INSULIN
F24S
1
man
polymer
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
no
FVNQHLCGSHLVEALYLVCGERGSFYTPKT
FVNQHLCGSHLVEALYLVCGERGSFYTPKT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
human
Homo
sample
9606
PANCREAS
Homo sapiens
pdbx_database_status
struct_conf
struct_conf_type
repository
Initial release
Version format compliance
Version format compliance
Derived calculations
Other
1
0
1994-01-31
1
1
2008-03-24
1
2
2011-07-13
1
3
2017-11-29
_pdbx_database_status.process_site
Y
BNL
1993-03-05
REL
REL
10
HAVEL
refinement
DGII
BRUNGER
refinement
X-PLOR
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
HIS
10
n
10
HIS
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
SER
24
n
24
SER
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
PRO
28
n
28
PRO
28
B
LYS
29
n
29
LYS
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
4
B
B
HG
HG1
SER
THR
24
30
1.30
2
B
B
THR
PRO
27
28
-146.07
9
B
B
THR
PRO
27
28
-146.50
1
B
ARG
22
0.314
SIDE CHAIN
2
B
ARG
22
0.278
SIDE CHAIN
3
B
ARG
22
0.308
SIDE CHAIN
4
B
ARG
22
0.287
SIDE CHAIN
5
B
ARG
22
0.140
SIDE CHAIN
6
B
ARG
22
0.198
SIDE CHAIN
7
B
ARG
22
0.309
SIDE CHAIN
8
B
ARG
22
0.303
SIDE CHAIN
9
B
ARG
22
0.136
SIDE CHAIN
10
B
ARG
22
0.261
SIDE CHAIN
1
-4.17
0.60
121.00
116.83
A
A
A
CB
CG
CD2
TYR
TYR
TYR
19
19
19
N
1
3.86
0.60
121.00
124.86
A
A
A
CB
CG
CD1
TYR
TYR
TYR
19
19
19
N
1
8.26
1.10
114.20
122.46
B
B
B
CA
CB
SG
CYS
CYS
CYS
19
19
19
N
1
-3.53
0.50
120.30
116.77
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
4
-3.70
0.60
121.00
117.30
B
B
B
CB
CG
CD2
TYR
TYR
TYR
26
26
26
N
5
-4.28
0.50
120.30
116.02
B
B
B
NE
CZ
NH2
ARG
ARG
ARG
22
22
22
N
6
6.96
1.10
114.20
121.16
A
A
A
CA
CB
SG
CYS
CYS
CYS
20
20
20
N
9
6.74
1.10
114.20
120.94
A
A
A
CA
CB
SG
CYS
CYS
CYS
11
11
11
N
1
A
ILE
2
-27.70
-53.71
1
A
GLU
4
-25.92
-52.39
1
A
CYS
7
-121.00
-53.51
1
A
SER
9
-125.19
-161.84
1
A
GLU
17
-25.79
-51.03
1
A
CYS
20
-28.09
-60.88
1
B
VAL
2
-115.35
59.19
1
B
VAL
18
-103.27
-78.93
1
B
PHE
25
-113.41
-96.84
1
B
THR
27
-118.36
57.99
2
A
CYS
6
-86.54
32.48
2
A
GLU
17
-28.35
-42.14
2
A
CYS
20
-65.67
-176.67
2
B
VAL
2
-117.35
70.85
2
B
ASN
3
9.64
55.11
2
B
LEU
6
-106.66
-81.32
2
B
CYS
7
76.92
-70.71
2
B
VAL
18
-89.80
-73.43
2
B
CYS
19
-126.92
-89.91
2
B
SER
24
-19.29
164.89
2
B
THR
27
-143.49
-62.11
3
A
GLU
4
-21.44
-57.94
3
A
CYS
11
-122.25
-168.37
3
A
CYS
20
-118.75
-168.34
3
B
ASN
3
-102.78
63.89
3
B
SER
9
-130.65
-35.46
3
B
CYS
19
-106.15
55.80
3
B
LYS
29
-147.96
59.92
4
A
VAL
3
-79.83
31.27
4
A
GLN
5
-108.27
-63.38
4
A
GLU
17
-26.32
-42.70
4
A
ASN
18
-27.75
-44.39
4
A
CYS
20
-35.82
169.23
4
B
ASN
3
-105.20
41.32
4
B
SER
9
-141.59
-41.51
4
B
VAL
18
-103.63
-67.26
4
B
GLU
21
104.15
-44.55
4
B
ARG
22
19.75
50.87
4
B
SER
24
7.62
86.43
4
B
PHE
25
5.26
-74.30
4
B
THR
27
-6.68
-53.31
4
B
PRO
28
-21.52
-59.77
5
A
GLU
4
-23.00
-40.73
5
A
CYS
7
-122.39
-55.74
5
A
THR
8
-109.97
68.32
5
A
SER
9
122.66
-175.02
5
A
TYR
19
-121.84
-51.02
5
A
CYS
20
-16.05
80.55
5
B
ASN
3
-119.19
51.60
5
B
HIS
10
-26.59
-52.50
5
B
CYS
19
-140.66
-70.64
5
B
PHE
25
-141.54
40.13
5
B
TYR
26
103.57
79.60
5
B
PRO
28
-54.41
80.41
5
B
LYS
29
-107.92
50.65
6
A
VAL
3
-104.74
49.85
6
A
SER
9
-128.15
-153.93
6
A
CYS
20
-116.47
77.29
6
B
VAL
2
-108.03
62.20
6
B
ASN
3
-21.89
85.30
6
B
CYS
7
109.56
37.62
6
B
SER
9
144.26
-9.42
6
B
CYS
19
-144.47
-67.49
6
B
GLU
21
34.20
58.77
6
B
ARG
22
-111.35
59.03
6
B
SER
24
15.02
-70.77
6
B
PHE
25
-105.32
51.48
6
B
PRO
28
-10.45
-67.63
6
B
LYS
29
-140.82
37.27
7
A
ILE
2
-107.64
-80.07
7
A
CYS
6
-65.11
4.98
7
A
SER
9
-134.12
-159.38
7
A
CYS
20
-115.00
-166.16
7
B
ASN
3
-112.86
55.49
7
B
CYS
7
-119.47
75.10
7
B
CYS
19
-107.06
52.93
7
B
GLU
21
-135.94
-50.46
7
B
PHE
25
-113.61
59.23
8
A
VAL
3
-28.60
-46.08
8
A
GLU
4
-26.41
-41.89
8
A
GLU
17
-27.02
-42.24
8
A
CYS
20
-45.23
156.67
8
B
TYR
16
-36.95
-37.64
8
B
LYS
29
-116.47
66.85
9
A
VAL
3
-96.74
41.09
9
A
LEU
13
-28.57
-57.22
9
A
GLU
17
-28.85
-38.15
9
A
ASN
18
-24.61
-42.01
9
B
ASN
3
-110.51
64.57
9
B
CYS
7
-130.87
-149.63
9
B
VAL
18
-93.39
-69.13
9
B
CYS
19
-120.01
-60.09
9
B
GLU
21
-95.13
53.57
9
B
SER
24
-118.47
78.55
9
B
PRO
28
-24.24
-53.35
10
A
CYS
6
-92.78
34.92
10
A
GLU
17
-33.58
-35.68
10
A
ASN
18
-31.78
-38.02
10
A
CYS
20
-18.85
-55.97
10
B
ASN
3
-115.60
54.92
10
B
GLU
21
40.49
82.91
10
B
SER
24
5.65
-75.62
10
B
THR
27
4.85
82.66
10
B
PRO
28
-53.80
103.79
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY SER (F24S) (NMR, REPRESENTATIVE PLUS 9 STRUCTURES)
PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS
1
N
N
2
N
N
A
ILE
2
A
ILE
2
HELX_P
A
THR
8
A
THR
8
1
H1
7
A
SER
12
A
SER
12
HELX_P
A
ASN
18
A
ASN
18
1
H2
7
B
SER
9
B
SER
9
HELX_P
B
CYS
19
B
CYS
19
1
H3
11
disulf
2.020
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.020
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.019
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
HORMONE
HORMONE
INS_HUMAN
UNP
1
90
P01308
INS_HUMAN
UNP
2
25
P01308
90
110
1HIQ
1
21
P01308
A
1
1
21
25
54
1HIQ
1
30
P01308
B
2
1
30
2
PHE
ENGINEERED MUTATION
SER
24
1HIQ
B
P01308
UNP
48
24
1
P 1